AB Science provides an update on its masitinib clinical program
05 août 2019 01h31 HE
|
AB Science
Paris, August 5 2019, 7.30am Update on masitinib clinical program AB Science SA (NYSE Euronext - FR0010557264 - AB) provides an update on its masitinib clinical program. The key points of...
Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
18 juil. 2019 10h40 HE
|
Rafael Pharmaceutical Inc.
Cranbury, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
01 juin 2019 09h00 HE
|
Bellicum Pharmaceuticals, Inc.
Data provides further evidence that GoCAR-T® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 mai 2019 16h14 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer
30 mai 2019 19h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
29 mai 2019 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
15 mai 2019 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Oncotelic Reports Clinical Validation of Drug Induce Xenogenization (DIX) For Treatment of Glioblastoma and Pancreatic Cancer (PC)
04 mars 2019 09h00 HE
|
Oncotelic Inc
Phase 2 Clinical Data Presented at ASCO-SITC Clinical Immuno-Oncology SymposiumXenogenization through chemotherapy-induced genetic mutations (alkylating agents such as temozolomide) or drug-induced...
PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA
04 févr. 2019 09h20 HE
|
PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the...
DrugCendR Announces Pancreatic Cancer Clinical Trial Data, New Member of Board of Directors and FDA Orphan Drug Designation
31 janv. 2019 03h31 HE
|
DrugCendR Inc.
LA JOLLA, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the...